Jamshedpur Reporter

Delveinsight Business Research LLP

The Geographic Atrophy market report covers emerging drugs, current treatment practices, market share of the individual therapies, current and forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Geographic Atrophy: An Overview

Geographic Atrophy (GA) is an advanced form of age-related macular degeneration (AMD). Macular degeneration also called age-related macular degeneration (AMD or ARMD) is a medical condition that may result in blurred or no vision in the center of the visual field. There are two basic types of macular degeneration: “dry” and “wet”. According to the “American Macular Degeneration Foundation,” approximately 85–90% of the cases of macular degeneration are the “dry” (atrophic) type.

Currently, there are no approved treatments present for Geographic Atrophy. However, currently, several therapies are in the pipeline to prevent the progression of Geographic Atrophy. The therapies are expected to hit the market in the coming years.

Geographic Atrophy Market Key Facts

• In the year 2020, the total prevalent case of Geographic Atrophy was 2,969,900+ in the 7MM. These cases are expected to grow with a significant CAGR in the study period.

• In the US, the total geographic atrophy cases by visual impairment were 397,400+, 662,400+, and 264,900+ for mild, moderate to severe, and patients going for surgery or having legal blindness, respectively, in 2020.

• Globally, more than 5 million people are affected by Geographic Atrophy. Also, as per the published study by the GER group, the global prevalence of GA is 0.66% in all ages.

• According to the research report published by the European Society of Retina Specialists named Retinal disease in Europe France accounted for the highest pooled prevalence estimate of late AMD at 3.3%, closely followed by Italy at 3.2%, Germany at 2.4%, and Spain at 2.3%.

Geographic Atrophy Market

The market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted Geographic Atrophy market size by analyzing the impact of current and emerging therapies in the market. It also provides a detailed assessment of the market drivers & barriers, unmet needs, and emerging technologies.

The report gives a thorough detail of the Geographic Atrophy market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MoA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.

Geographic Atrophy Epidemiology

The epidemiology section covers insights into the historical and current Geographic Atrophy patient pool and forecasted trends for every seven major countries (7MM)  from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.  

Geographic Atrophy (GA) Epidemiology Segmentation –

• Total Prevalent Cases of Geographic Atrophy

• Total Diagnosed cases of Geographic Atrophy

• Treated cases of Geographic Atrophy Total

• Diagnosed cases of Geographic Atrophy by Age Distribution

• Total Geographic Atrophy Cases by Visual Impairment

Geographic Atrophy Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Geographic Atrophy market or expected to get launched in the market during the study period. The analysis covers Geographic Atrophy market uptake by drugs; patient uptake by therapies; and sales of each drug. 

Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

The report also covers the Geographic Atrophy Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II, and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyses the recent Development such as collaborations, acquisitions, and mergers, licensing patent details, and other information for emerging therapies.

Request for Sample PDF Report – https://www.delveinsight.com/sample-request/geographic-atrophy-ga-market

Geographic Atrophy Therapeutics Analysis

The Geographic Atrophy (GA) market dynamics is anticipated to change in the coming years owing to the launch of novel drugs and the rise in healthcare spending across the world.

Some of the key companies in the Geographic Atrophy (GA) Market include:

• Apellis Pharmaceuticals

• Iveric Bio

• Hemera Biosciences

• Gyroscope Therapeutics

• Stealth BioTherapeutics

• Roche (Genentech)

• CellCure Neurosciences

And many others.

Geographic Atrophy (GA) Therapies covered in the report include:

• Zimura (Avacincaptad Pegol)

• Pegcetacoplan

• HMR59/AAVCAGsCD59

• Risuteganib

• Elamipretide

• ALK-001

• Palucorcel/CNTO 2476

And many more.

Get More Detailed Insights Into the Emerging Therapies & Key Companies –   https://www.delveinsight.com/sample-request/geographic-atrophy-ga-market

Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Geographic Atrophy Competitive Intelligence Analysis

4. Geographic Atrophy Market Overview at a Glance

5. Geographic Atrophy Disease Background and Overview

6. Geographic Atrophy Patient Journey

7. Geographic Atrophy Epidemiology and Patient Population

8. Geographic Atrophy Treatment Algorithm, Current Treatment, and Medical Practices

9. Geographic Atrophy Unmet Needs

10. Key Endpoints of Geographic Atrophy Treatment

11. Geographic Atrophy Marketed Products

12. Geographic Atrophy Emerging Therapies

13. Geographic Atrophy Seven Major Market Analysis

14. Attribute Analysis

15. Geographic Atrophy Market Outlook (7 major markets)

16. Geographic Atrophy Access and Reimbursement Overview

17. KOL Views on the Geographic Atrophy Market.

18. Geographic Atrophy Market Drivers

19. Geographic Atrophy Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF Report – https://www.delveinsight.com/sample-request/geographic-atrophy-ga-market

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.

Other Latest Reports By DelveInsight

Paraganglioma Market

DelveInsight’s “Paraganglioma Market” report delivers an in-depth understanding of the historical and forecasted epidemiology, the Paraganglioma market size, shares, and trends analysis in the 7MM (i.e the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan) as well as the emerging therapies and key companies in the therapeutic domain.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/